Theravance Biopharma, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
TBPH$17.030.0%Stored close · as of Sep 23, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| | | | | | | Incorporated by Reference | ||
| ExhibitNumber | Exhibit Description | Filed Herewith | Form | FilingDate/PeriodEnd Date | ||||
| | | | | | | | | |
| 31.1 | | Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended | | X | | | | |
| | | | | | | | | |
| 31.2 | | Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended | | X | | | | |
| | | | | | | | | |
| 32(1) | | Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | | X | | | | |
| | | | | | | | | |
| 101 | | Financial statements from the quarterly report on Form 10-Q of the Company for the quarter ended September 30, 2025, formatted in iXBRL: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss), (iii) Condensed Consolidated Statements of Shareholders’ Equity, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) the Notes to the Condensed Consolidated Financial Statements | | X | | | | |
| | | | | | | | | |
| 104 | | Cover Page Interactive Data File (Formatted in iXBRL and contained in Exhibit 101) | | X | | | | |
| (1) | The certifications provided as Exhibit 32 are being furnished to accompany the Report pursuant to 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.